Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19 or CD19-BCMA CAR-T in Autoimmune Diseases
NCT06548607Phase 1Recruiting
- Sponsor
- Bioheng Therapeutics
- Start
- Sep 2024
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) and BG2205 in systemic lupus erythematosus (SLE), systemic sclerosis (SSc), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and 2 more, sponsored by Bioheng Therapeutics. Primary endpoint: Adverse Events at 2 years. Started Sep 2024; status: recruiting.
02
Drugs
Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)BG2205
03
Conditions
systemic lupus erythematosus (SLE)systemic sclerosis (SSc)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathy (IIM)Sjögren's syndrome
Beyond the preview
Go deeper on NCT06548607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06548607.